- A blood test for breast cancer screening: Syantra receives CE mark approval for its breast cancer test based on the Syantra DX liquid biopsy platform
CALGARY, AB, April 18, 2023 /PRNewswire/ -- Syantra announced today that it has obtained CE Mark for the Syantra DXTM Breast Cancer Test. Syantra DXTM Breast Cancer is a minimally invasive blood test for the detection of an active signature of breast cancer, in the early stages, when it is easier to treat. The test assesses gene expression patterns of 12 unique biomarkers through a custom qPCR process using proprietary software that includes algorithms derived from machine learning. Securing the CE mark allows the company to market the blood test in the European Union and other countries that recognize the designation.
"Getting the CE Mark for the Syantra DXTM Breast Cancer Test brings us one step closer to helping women around the world detect breast cancer at its earliest stages, when it is most treatable," said Kristina Rinker, MD. , Co-Founder and Chief Scientific Officer of Syantra.
"Syantra's blood-based test may help improve breast cancer detection in women at high risk of developing breast cancer, particularly young women with a genetic predisposition and women with dense breasts or diverse ethnic origins. For such women, standard screening mammography may be inadequate and more sensitive tests are urgently needed," said Massimo Cristofanilli, MD, professor of medicine, director of breast medical oncology and associate director of precision medicine at the Sandra and Edward Meyer Cancer Center. at Weill Cornell Medicine. Dr. Cristofanilli also serves as a member of the paid scientific advisory board of Syantra Inc.
Syantra is a precision biotechnology company that is changing the way cancer is detected and treated. Its flagship product, Syantra DXTM Breast Cancer, is a high-throughput, minimally invasive blood test for the detection of breast cancer in the early stages.
For more information about Syantra and the Syantra DXTM Breast Cancer Test, visit: www.syantra.com
Social networks: LinkedIn, Twitter, Facebook, Instagram
Photo - https://mma.prnewswire.com/media/2052918...
View original content: https://www.prnewswire.com/news-releases/syantra-recibe-la-aprobacion-de-la-marca-ce-para-su-prueba-de-cancer-de-mama-301799700.html